First patients to test experimental cancer drug in early safety trial
NCT ID NCT06694480
Summary
This is the first study in people to test a new cancer drug called FID-022. The main goal is to find a safe dose and understand the side effects for patients with advanced solid tumors that have no standard curative treatments. Researchers will also measure how the drug moves through the body and look for any early signs that it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
USC/Norris Comprehensive Cancer Center and Hospital
RECRUITINGLos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.